Stifel Financial Corp Has $494,000 Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Stifel Financial Corp grew its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 3.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 99,133 shares of the company’s stock after purchasing an additional 3,733 shares during the period. Stifel Financial Corp’s holdings in TScan Therapeutics were worth $494,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in TCRX. Dimensional Fund Advisors LP purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at approximately $70,000. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the 3rd quarter valued at $78,000. The Manufacturers Life Insurance Company purchased a new stake in shares of TScan Therapeutics in the second quarter valued at $90,000. MetLife Investment Management LLC boosted its position in shares of TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after buying an additional 13,164 shares during the period. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of TScan Therapeutics in the second quarter worth $134,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Price Performance

TCRX opened at $3.11 on Friday. The stock has a fifty day moving average price of $4.37 and a 200 day moving average price of $5.53. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics, Inc. has a 1 year low of $2.60 and a 1 year high of $9.69. The stock has a market cap of $165.98 million, a price-to-earnings ratio of -2.93 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.86 million. Analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.